Office Care of Patients After Myocardial Infarction

References

• Miniño AM, Heron MP, Smith BL; Division of Vital Statistics. Centers for Disease Control and Prevention (CDC) National Vital Statistics Reports. Vol. 54, No. 19. June 28, 2006. http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_l9.pdf. Accessed September 2007.
   Google Scholar
• Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007; 356(23): 2388–2398.
   PubMed Web of Science ®Google Scholar
• Smaha LA; American Heart Association. The American Heart Association Get With The Guidelines program. Am Heart J. 2004; 148(suppl 5)S46–S48.
   Google Scholar
• Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2001; 161 (13): 1621–1628.
   Google Scholar
• Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113(19): 2363–2372.
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Jackson R, Pearson TA, et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation. 2004; 109(25): 3112–3121.
   PubMedGoogle Scholar
• Eknoyan G, Levin NW. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Disease. 2002; 39(2 suppl 1): S1–S226.
   PubMedGoogle Scholar
• Rana JS, Mukamal KJ, Morgan JP, Muller JE, Mittleman MA. Obesity and the risk of death after acute myocardial infarction. Am Heart J. 2004; 147(5): 841–846.
   Google Scholar
• Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004; 110(9): e82–e292.
   PubMedGoogle Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2): 227–239.
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007; 116(7): e803–e877.
   Google Scholar
• Fletcher GF, Bufalino V, Costa F, et al. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiology. 2007; 99(6C): 1E–35E.
   Google Scholar
• Reiffei JA. Practical algorithms for pharmacologic management of the post myocardial infarction patient. Clin Cardiol. 2005; 28(11 suppl 1): 28–37.
   Google Scholar
• Dalen JE. Aspirin to prevent heart attack and stroke: what's the right dose? Am J Med. 2006; 119(3): 198–202.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14): 1001–1009.
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998(19); 339: 1349–1357.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002(9326); 360: 7–22.
   PubMed Web of Science ®Google Scholar
• Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids and cardiovascular disease. Circulation. 2002; 106(21): 2747–2757.
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Secondary prevention of coronary artery disease with omega-3 fatty acids. Am J Cardiology. 2006; 98(4A): 61i–70i.
   Google Scholar
• Young JB, Dunlap ME, Pfeffer MA, et al; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004; 110: 2618–2626.
   PubMed Web of Science ®Google Scholar
• American Heart Association Nutrition Committee; Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006; 114(1): 82–92.
   Google Scholar
• Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993; 328(20): 1450–1456.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993; 328(20): 1444–1449.
   PubMed Web of Science ®Google Scholar
• Bønaa KH, Njølstad l, Ueland PM, et al; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 54(15): 1578–1588.
   Google Scholar
• Taylor CB, Youngblood ME, Catellier D, et al; ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005; 165(10): 1154–1160.
   Google Scholar
• Jiang W, Davidson JR. Antidepressant therapy in patients with ischemic heart disease. Am Heart J. 2005; 150: 871–881.
   PubMed Web of Science ®Google Scholar